WorldPharmaNews
Search ...
Home
Business
Research
Events
Regulatory
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
www.bms.com
.
Bristol-Myers Squibb RSS Channel
Filters
Display #
5
10
15
20
25
30
50
100
All
Filter
List of articles in category Bristol-Myers Squibb
Title
Published Date
U.S. Food and Drug Administration approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) for patients with hepatocellular carcinoma (HCC) previously treated with sorafenib
11 March 2020
Voluntis and Bristol-Myers Squibb to co-develop digital therapeutics for oncology
04 March 2020
BioMotiv and Bristol-Myers Squibb announce the launch of Anteros Pharmaceuticals
04 February 2020
U.S. Food and Drug Administration accepts for Priority Review Bristol-Myers Squibb's application for Opdivo (nivolumab) plus Yervoy (ipilimumab) in first-line non-small cell lung cancer
17 January 2020
Bristol-Myers Squibb completes divestment of manufacturing facility in Anagni, Italy
07 January 2020
Bristol-Myers Squibb completes acquisition of Celgene, creating a leading biopharma company
21 November 2019
Bristol-Myers Squibb and Pfizer announce randomized, controlled trial to evaluate the effect of atrial fibrillation screening on health outcomes in older individuals
15 November 2019
Bristol-Myers Squibb awards "Golden Tickets" for LabCentral to Carmine Therapeutics, STIMIT
31 October 2019
The Bristol-Myers Squibb-Pfizer Alliance and Fitbit collaborate to address gaps in atrial fibrillation detection with the aim of accelerating diagnosis
18 October 2019
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement
18 July 2019
Bristol-Myers Squibb provides update on pending merger with Celgene
24 June 2019
Bristol-Myers Squibb announces post-closing leadership team
05 June 2019
Award-winning actor and producer Sterling K. Brown joins Bristol-Myers Squibb in effort to share stories of What It's Like to Live with Cancer Today
16 May 2019
Bristol-Myers Squibb reports first quarter financial results
25 April 2019
Bristol-Myers Squibb shareholders approve Celgene acquisition
12 April 2019
European Commission approves Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) for first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma
15 January 2019
Bristol-Myers Squibb to acquire Celgene to create a premier innovative biopharma company
03 January 2019
Bristol-Myers Squibb and Boston Medical Center announce research collaboration to investigate markers of immuno-oncology response and resistance
17 December 2018
Bristol-Myers Squibb awards "Golden Tickets" for LabCentral to ReviveMed, Strand Therapeutics
26 November 2018
Bristol-Myers Squibb and Compugen announce clinical collaboration to evaluate therapeutic regimen in advanced solid tumors
11 October 2018
Start
Prev
1
2
3
4
5
6
7
8
9
10
Next
End
Business & Industry
Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
Pfizer expands 'An Accord for a Healthier World' product offering to include full portfolio for greater benefit to 1.2 billion people in 45 lower-income countries
Acquisition of Neogene Therapeutics completed
Bayer to accelerate drug discovery with Google Cloud's high-performance compute power
NextPoint Therapeutics announces $80 million Series B financing co-led by Leaps by Bayer and Sanofi Ventures to advance novel immuno-oncology programs
Research & Development
Keys to making immunotherapy work against pancreatic cancer found in tumor microenvironment
Discovery of anti-cancer chemistry makes skullcap fit for modern medicine
Coordination of COVID-19 vaccine clinical trials produces a 'treasure trove' of data and a model for the future
Power of cancer drugs may see boost by targeting newly ID'd pathway
A soybean protein blocks LDL cholesterol production, reducing risks of metabolic diseases
500,000 missed out on blood pressure lowering drugs during pandemic
Modified CRISPR-based enzymes improve the prospect of inserting entire genes into the genome to overcome diverse disease-causing mutations
Conferences & Events
SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
SAE Media Group's 6th annual 3D Cell Culture Conference
CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
CPHI Excellence in Pharma Award Winners 2022
CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index
Regulatory Affairs
FDA grants Accelerated Approval for Alzheimer's disease treatment
FDA approves new HIV drug for adults with limited treatment options
FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
FDA approves first gene therapy to treat adults with Hemophilia B
FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
You are here:
Home
Bristol-Myers Squibb